The I-mode confinement regime at ASDEX Upgrade: global propert ies and characterization of strongly intermittent density fluctuations

Properties of the I­mode confinement regime on the ASDEX Upgrade tokamak are summarized. A weak dependence of the power threshold for the L­I transition on the toroidal magnetic field strength is found. During improved confinement, the edge radial electric field well deepens. Stability calculations show that the I­mode pedestal is peeling­ballooning stable. Turbulence investigations reveal strongly intermittent density fluctuations linked to the weakly coherent mode in the confined plasma, which become stronger as the confinement quality increases. Across all investigated structure sizes ( ≈ ⊥ k 5 – 12 cm − 1 , with ⊥ k the perpendicular wavenumber of turbulent density fluctuations), the intermittent turbulence bursts are observed. Comparison with bolometry data shows that they move poloidally toward the X­point and finally end up in the divertor. This might be indicative that they play a role in inhibiting the density profile growth, such that no pedestal is formed in the edge density profile.European Union (EUROfusion 633053)European Union (EUROfusion AWP15­ENR­09/IPP­02

On non-zero space average density perturbation effects in tokamak plasma reflectometer signals

12th International Congress on Plasma Physics, 25-29 October 2004, Nice (France)The effects of the non-zero average density perturbation on phase and amplitude measured by reflectometry are presented. The non-zero average density perturbation on the phase variation can be seen as an index effect as soon as the shape of the density perturbation does not introduce spectral effects. Amplitude modulation in time follows generally the properties of the cut-off layer seen as a mirror but some specific situations produce a time modulation two times higher than the input time variation of the density perturbation as observed in Tore Supra. The introduction of secondary cut-off can exhibit this effect as shown in 2D simulations

Influence of plasma turbulence on microwave propagation

It is not fully understood how electromagnetic waves propagate through plasma density fluctuations when the size of the fluctuations is comparable with the wavelength of the incident radiation. In this paper, the perturbing effect of a turbulent plasma density layer on a traversing microwave beam is simulated with full-wave simulations. The deterioration of the microwave beam is calculated as a function of the characteristic turbulence structure size, the turbulence amplitude, the depth of the interaction zone and the size of the waist of the incident beam. The maximum scattering is observed for a structure size on the order of half the vacuum wavelength. The scattering and beam broadening was found to increase linearly with the depth of the turbulence layer and quadratically with the fluctuation strength. Consequences for experiments and 3D effects are considered.Comment: 16 pages, 13 figures. This is an author-created, un-copyedited version of an article submitted for publication in Plasma Physics and Controlled Fusion. IoP Publishing Ltd is not responsible for any errors or omissions in this version of the manuscript or any version derived from i

The tyrosine kinase inhibitor ZD6474 inhibits tumour growth in an intracerebral rat glioma model

Malignant glioma is characterised by extensive neovascularisation, principally influenced by vascular endothelial growth factor (VEGF). ZD6474 is a potent inhibitor of VEGF-R2 tyrosine kinase activity, but with additional inhibitory effects on other growth factors. In this study, we have investigated the effects of ZD6474 with regard to tumour growth, neovascularisation, proliferation and apoptosis in the intracerebral rat glioma model, BT4C. ZD6474 (50 and 100 mg kg−1) was given as a daily oral gavage. Animals were killed on day 19 and tumour volume was measured. Sections were stained for factor VIII, Ki-67 and for apoptosis. The ability of ZD6474 to inhibit cell growth directly was examined in vitro, using the glioma cell line BT4C and the transformed rat brain endothelial cell line RBE4. Cell growth was analysed with fluorometric microculture cytotoxicity assay to quantify the cytotoxic effects. ZD6474 significantly decreased tumour volume compared to controls. Microvascular density increased after treatment with ZD6474, and tumour cell proliferation index was reduced. There was also an increase in tumour cell apoptosis. In vitro, the growth of both cell lines was significantly reduced. The results reported justify further experimental investigations concerning the effects of ZD6474 in malignant glioma alone or in combination with other modalities

Concurrent administration of Docetaxel and Stealth® liposomal doxorubicin with radiotherapy in non-small cell lung cancer : excellent tolerance using subcutaneous amifostine for cytoprotection

The substantial augmentation of the radiation sequelae during chemo–radiotherapy with novel drugs masks the real potential of such regimens. In this study we examined whether subcutaneous administration of amifostine can reduce the toxicity of a highly aggressive chemo–radiotherapy scheme with Stealth® liposomal doxorubicin (Caelyx®) and Docetaxel (Taxotere®) in non-small cell lung cancer. Twenty-five patients with stage IIIb non-small cell lung cancer were recruited in a phase I/II dose escalation trial. The starting dose of Taxotere® was 20 mg m−2 week and of Caelyx® was 15 mg m−2 every two weeks, during conventionally fractionated radiotherapy (total dose of 64 Gy). The dose of Taxotere®/Caelyx® was, thereafter, increased to 20/25 (five patients) and 30/25 mg m−2 (15 patients). Amifostine 500 mg was given subcutaneously before each radiotherapy fraction, while an i.v. amifostine dose of 1000 mg preceded the infusion of docetaxel. The ‘in-field’ radiation toxicity was low. Grade 3 esophagitis occurred in 9 out of 25 (36%) patients. Apart from a marked reduction of the lymphocyte counts, the regimen was deprived from any haematological toxicity higher than grade 1. No other systemic toxicity was noted. The CR and CR/PR rates in 15 patients treated at the highest dose level was 40% (6 out of 15) and 87% (13 out of 15) respectively. It is concluded that the subcutaneous administration of amifostine during high dose Taxotere®/Caelyx® chemo–radiotherapy is a simple and effective way to render this aggressive regimen perfectly well tolerated, by reducing the systemic and the ‘in-field’ toxicity to the levels expected from simple conventional radiotherapy. The impressive tolerance and the high CR rate obtained encourages the conduct of a relevant randomized trial to assess an eventual survival benefit in patients with non-small cell lung cancer

ZD6474 – a novel inhibitor of VEGFR and EGFR tyrosine kinase activity

Angiogenesis is crucial for maintaining the supply of oxygen and nutrients required to support solid tumour growth. Inhibitors of tumour blood vessel formation are therefore being sought, in particular, inhibitors of vascular endothelial growth factor-A (VEGF)-signalling, which has a pivotal role in stimulating neovascular growth and survival. ZD6474 is an orally bioavailable inhibitor of VEGF receptor-2 tyrosine kinase activity that in preclinical studies has been shown to inhibit both VEGF-induced signalling in endothelial cells and tumour-induced angiogenesis. Consistent with inhibition of angiogenesis, once-daily oral dosing of ZD6474 produced significant broad-spectrum antitumour activity in a panel of histologically diverse human tumour xenografts. In addition to its antiangiogenic properties, ZD6474 also has activity against the epidermal growth factor receptor (EGFR) tyrosine kinase, which could impart a direct inhibitory effect on tumour cell growth and survival. This may be particularly relevant in tumours with a dependency upon EGFR signalling, for example in certain tumours harbouring activating mutations in EGFR. RET kinase has also been identified as a third target for ZD6474. This review summarises preclinical studies with this unique agent and considers its future direction in cancer treatment